withdrawn

Bucetin (3-Hydroxy-p-butyrophenetidide) is a pharmaceutical drug that functions as an analgesic and antipyretic. It was withdrawn from use in 1986 due to renal toxicity.

Bithionol (Actamer), formerly marketed as an active ingredient in various topical drug products, was shown to be a potent photosensitizer with the potential to cause serious skin disorders. Approvals of the NDA's for bithionol drug products were withdrawn on October 24, 1967.

Pergolide mesylate salt(LY127809) is a long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES.

Fluproquazone is a quinazolinone derivative with potent antipyretic, analgesic, and anti-inflammatory effects. However, it was withdrawn during development due to liver toxicity.

Zimelidine is a serotonin uptake inhibitor formerly used for depression, but was withdrawn worldwide because of the risk of Gullain-Barre syndrome associated with its use.

ML 23 is a melatonin analogue in the treatment and management of Parkinson's disease. ML-23 is a potential clinical candidate for the treatment of PD, and the present study has been undertaken to determine the efficacy of ML-23 in the 1-methyl-4-phenyl, 1

Muzolimine is pyrazole diuretic with long duration and high capacity of action. It was proposed for kidney failure and hypertension but was withdrawn worldwide because of severe neurological effects.

Zimeldine hydrochloride hydrate is a serotonin uptake inhibitor that was formerly used for depression but was withdrawn worldwide in September 1983 because of the risk of Guillain-Barre Syndrome associated with its use.

Thenalidine is an antihistamine with anticholinergic properties used as an antipruritic drug. It was withdrawn from the US, Canadian, and UK markets due to a risk of neutropenia. Thenalidine is an antagonist of the H1-receptor.

Nialamide monohydrochloride is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was used as an antidepressant. It was withdrawn by Pfizer several decades ago due to the risk of hepatotoxicity.

Bamlanivimab, an Anti-Human SARS-CoV-2 monoclonal antibody (mAb), was the first of its kind to receive Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in November 2020 for COVID-19 treatment. However, its authorization was withdrawn in April 2021 due to emerging SARS-CoV-2 variants resistant to the antibody [1].